查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985686

基因组检测市场：全球市场按产品类型、技术、服务类型、应用和最终用户分類的预测——2026-2032年

Genome Testing Market by Product Type, Technology, Service Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因组检测市场价值将达到 224.5 亿美元，到 2026 年将成长至 255.1 亿美元，到 2032 年将达到 552.3 亿美元，复合年增长率为 13.72%。

主要市场统计数据
基准年 2025 224.5亿美元
预计年份：2026年 255.1亿美元
预测年份 2032 552.3亿美元
复合年增长率 (%) 13.72%

本文对基因组检测在医疗保健创新、诊断、研究和消费者服务中的战略重要性进行了简明扼要而又全面的概述。

基因组检测已从小众研究应用发展成为涵盖临床诊断、药物研发和消费者健康服务等核心功能。定序化学、微阵列平台和聚合酵素链锁反应(PCR) 技术的进步，在提高分析深度的同时，也缩短了许多工作流程的出结果时间。同时，从分析流程到云端原生资料存储，软体和服务层已成为将原始资料转化为临床可用或商业性价值成果的关键基础。

科技、法规和经营模式的新转折点正在重塑我们开发、提供基因组检测以及从中获利的方式。

基因组检测领域正经历着一场变革性的转变，这主要得益于技术的同步进步、监管要求的不断变化以及经营模式的演变。次世代定序技术的进步提高了处理能力并降低了每个样本的复杂性，而改进的PCR变体和高解析度微阵列平台则实现了快速、可直接用于临床的检测。随着技术的成熟，软体定义的工作流程和分析服务在端到端价值链中占据了越来越大的份额，这为供应商和服务供应商创造了新的收入来源，同时也带来了新的合规责任。

2025 年美国实施的关税措施对基因组检测零件、采购和营运的全球供应链的累积影响。

美国2025年实施的关税措施对基因组检测的营运和策略产生了累积和多方面的影响。最直接的影响体现在实体商品的流通。对于高精度仪器、专用耗材和专有试剂盒而言，由于製造地有限且高度集中，关税导致接收成本增加，采购週期延长。对于依赖即时（JIT）补货模式的机构而言，这些变化带来了库存和营运资金的挑战，并迫使其重新评估与供应商的关係和合约条款。

详细的细分洞察，揭示产品类型、技术、应用、最终用户和服务类别如何相互作用，从而塑造需求动态。

要了解市场，需要对产品、技术、应用、终端用户和服务类型进行多层次细分，从而揭示需求、临床价值和创新之间的交集。从产品角度来看，仪器、试剂盒、试剂和耗材以及软体和服务各自发挥独特的经济和监管作用。微阵列扫描仪、PCR仪和定序仪等仪器是资本密集核心设备，决定了实验室工作流程的处理能力和技术范围。从EXOME试剂盒到标靶基因试剂盒和全基因组试剂盒，各种试剂盒能够标准化流程并缩短结果获取时间。另一方面，试剂和耗材则有助于维持检测的准确性和操作稳定性。分析服务、数据储存软体和定序服务通常将原始数据转化为可解释和共用的数据，从而确定检测结果是否具有临床应用价值。

美洲、欧洲、中东、非洲和亚太地区的区域趋势和跨境因素正在影响准入、监管和创新。

区域趋势正在以不同的方式影响美洲、欧洲、中东、非洲和亚太地区的医疗服务取得、监管和商业化策略。在美洲，私人实验室网路、支付方结构和成熟的法规结构之间的相互作用正在加速成熟诊断测试的临床应用，同时也催生了对差异化、可报销价值提案的需求。北美和南美市场不同的采购惯例和价格敏感度体现在针对特定区域制定的商业化和分销策略。

领先基因组检测公司的策略概况和竞争定位：重点介绍技术和服务模式的核心差异化因素

基因组检测领域的主要企业拥有多元化的策略重点，涵盖仪器创新、整合耗材生态系统、软体主导的分析以及端到端定序服务等各个面向。一些企业正集中研发次世代定序化学和仪器工程技术，以实现更高的通量和更低的工作量。另一些企业则透过模组化试剂盒组合和试剂供应链建构竞争优势，确保持续收入并简化检查室检验。还有一些企业专注于软体平台和分析服务，将基因组分析结果转化为临床可用的报告，并着重于互通性、资料安全性和合规性。

为产业领导者提供切实可行的操作建议，以加速采用、确保供应连续性、优化临床工作流程和扩大应用范围。

产业领导者应采取一系列切实可行的操作措施，以加速技术应用、维持营运连续性并扩大临床应用范围。首先，应优先考虑供应链韧性，具体措施包括对关键仪器、试剂和耗材的多个供应商进行认证，并在条件允许的情况下建立区域采购和生产合作关係。这将有助于降低关税波动和物流中断带来的风险，同时缩短临床检查室认证週期。

透明的调查方法，解释了资料收集、专家访谈、检验过程以及支撑基因组检测结果的分析框架。

本调查方法结合了一手和二手调查，旨在提供检验且切实可行的见解。一手资料收集包括对各领域专家进行结构化访谈，这些领域涵盖检查室营运、临床实践和业务部门领导，以了解实际操作中的限制和实施驱动因素。除访谈外，还与采购和品质保证专家进行了有针对性的对话，揭示了供应链的薄弱环节和检验计划。

简明结论总结了影响基因组检测的技术进步、政策转变、细分模式和区域因素的关键要点。

结论整合了源自技术进步、政策趋势、市场区隔复杂性和区域差异的核心策略洞察。技术创新不断拓展分析可能性，同时也增加了与资讯学和检验工作流程整合的需求。政策和监管的变化要求儘早并持续参与，以确保临床适用性和病人安全；市场細項分析揭示了诊断、消费和研究市场需要差异化策略。区域趋势进一步增加了业务扩张的复杂性，因此，建立扎根于本地的伙伴关係和供应链策略对于确立可持续的市场地位至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：基因组检测市场：依产品类型划分

  • 装置
    • 微阵列扫描仪
    • PCR装置
    • 序列器
  • 成套工具
    • EXOME试剂盒
    • 目标基因试剂盒
    • 全基因组试剂盒
  • 试剂和耗材
  • 软体服务
    • 分析服务
    • 资料储存软体
    • 定序服务

第九章：基因组检测市场：依技术划分

  • 微阵列
    • 表达式数组
    • SNP晶片
  • 次世代定序
    • Illumina
    • Ion Torrent
  • PCR
    • 数位PCR
    • qPCR
  • 桑格定序

第十章：基因组检测市场：依服务类型划分

  • 面向一般消费者
    • 祖先
    • 生活方式与健康
      • 健身
      • 营养
  • 诊断
    • 临床诊断
    • 伴随诊断
  • 调查
    • 临床研究
    • 临床前研究

第十一章：基因组检测市场：依应用领域划分

  • 基因疾病检测
    • 携带者筛检
    • 罕见疾病
  • 传染病检查
    • 细菌检测
    • 病毒检测
  • 肿瘤科检查
    • 液态生物检体
    • 固态肿瘤分析
  • 药物基因体学
  • 产前检查

第十二章：基因组检测市场：依最终用户划分

  • 学术机构
    • 研究中心
    • 大学
  • 生物技术和製药公司
    • 生技公司
    • 製药公司
  • 诊断检测实验室
    • 医院检查室
    • 独立检测实验室
  • 消费者
    • 线上提供者
    • 零售诊所
  • 医院和诊所
    • 大型医院
    • 专科诊所

第十三章：基因组检测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：基因组检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：基因组检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国基因组检测市场

第十七章：中国基因组检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics
  • 23andMe, Inc
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche, Ltd.
  • Freenome Holdings, Inc.
  • GeneDx, LLC
  • Genomic Testing Cooperative
  • Helix OpCo, LLC
  • Illumina, Inc.
  • Merck KGaA
  • New England Biolabs, Inc.
  • Novogene Co, Ltd.
  • Oxford Nanopore Technologies PLC
  • PerkinElmer Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Takara Bio Inc
  • Thermo Fisher Scientific Inc.
  • Ultima Genomics, Inc.
  • VWR International, LLC
Product Code: MRR-647F3A880B41

The Genome Testing Market was valued at USD 22.45 billion in 2025 and is projected to grow to USD 25.51 billion in 2026, with a CAGR of 13.72%, reaching USD 55.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.45 billion
Estimated Year [2026] USD 25.51 billion
Forecast Year [2032] USD 55.23 billion
CAGR (%) 13.72%

A concise yet comprehensive opening framing the strategic importance of genome testing for healthcare innovation, diagnostics, research, and consumer services

Genome testing has moved from niche research applications into a core capability across clinical diagnostics, pharmaceutical development, and consumer health services. Advances in sequencing chemistry, microarray platforms, and polymerase chain reaction technologies have increased analytical depth while driving down time-to-result for many workflows. At the same time, software and service layers-ranging from analysis pipelines to cloud-native data storage-have become essential enablers that translate raw data into clinically actionable or commercially meaningful outputs.

This report frames genome testing as an ecosystem, not simply a collection of instruments. Instruments such as sequencers, microarray scanners, and PCR machines now operate alongside consumables including kits, reagents, and specialized consumables that are designed for particular assay workflows. Separate but adjacent, analysis services and data management platforms are transforming how results are validated, shared, and secured. By situating these elements together, stakeholders can better understand where investment, regulation, and partnership will create the largest operational and clinical leverage. The introduction establishes that context and orients readers to the interdependencies that determine value creation in genome testing.

Emerging technological, regulatory, and business model inflection points that are reconfiguring how genome testing is developed, delivered, and monetized

The landscape for genome testing is undergoing transformative shifts driven by concurrent advances in technology, changes in regulatory expectations, and evolving business models. Next generation sequencing improvements are increasing throughput and lowering per-sample complexity, while enhanced PCR variants and high-resolution microarray platforms extend capabilities into rapid, point-of-care compatible assays. As technology matures, software-defined workflows and analysis services are taking a larger share of the end-to-end value chain, creating new revenue and compliance responsibilities for vendors and service providers.

Regulatory regimes are catching up to these technical advances, imposing stricter requirements around analytical validation, data provenance, and patient privacy. Meanwhile, reimbursement frameworks and clinical acceptance continue to evolve, changing incentives for diagnostic adoption. Business models are also shifting: instrument sales remain important, but recurring revenue from kits, reagents, and subscription-based analysis is increasingly central. These shifts create opportunities for differentiated value propositions, yet they also heighten the importance of supply chain resilience, rigorous quality management, and strategic collaborations across manufacturers, laboratories, and clinical networks. Together, these forces are redefining where competitive advantage will accrue in genome testing.

Cumulative implications of United States tariff measures in 2025 on global supply chains for genome testing components, procurement, and operations

United States tariff measures enacted in 2025 have a cumulative, multi-dimensional effect on genome testing operations and strategy. The most immediate impact has been on the movement of physical goods: high-precision instruments, specialized consumables, and proprietary kits experience increased landed costs and elongated procurement cycles when tariffs intersect with limited, highly concentrated manufacturing footprints. For organizations that have depended on just-in-time replenishment, these changes raise inventory and working capital considerations and force a re-evaluation of vendor relationships and contractual terms.

Beyond procurement, tariffs amplify indirect operational pressures. Laboratory budgets must absorb higher input prices or reallocate spend away from other projects, which can delay validation studies or limit pilot deployments. At the same time, some suppliers are responding with regionalized manufacturing or alternate distribution strategies that can improve medium-term resilience but require new qualification steps for laboratories and clinical partners. These dynamics are also influencing contract negotiations, pricing strategies, and the calculus for vertical integration versus outsourcing. In short, the tariff environment is reshaping how organizations think about sourcing, contingency planning, and the cost of delivering reliable genomic services.

Detailed segmentation insights revealing how product types, technologies, applications, end users, and service categories interplay to shape demand dynamics

Understanding the market requires a layered view of product, technology, application, end user, and service type segmentation to reveal where demand, clinical value, and innovation converge. From a product perspective, instruments, kits, reagents and consumables, and software and services occupy distinct economic and regulatory roles. Instruments such as microarray scanners, PCR machines, and sequencers are capital-intensive anchors that determine the throughput and technical envelope of laboratory workflows. Kits-ranging from exome kits to targeted gene and whole genome kits-standardize procedures and shorten time-to-result while reagents and consumables maintain assay fidelity and operational stability. Analysis services, data storage software, and sequencing services convert raw output into interpretable, shareable data and often determine whether tests are clinically actionable.

When the market is viewed through the lens of technology, discrete platforms reveal complementary strengths and trade-offs. Microarray technologies, with expression arrays and SNP arrays, enable established, cost-effective profiling for defined use cases; next generation sequencing platforms, including dominant architectures, enable broader genomic coverage with different chemistry and data demands; and PCR-based approaches such as digital PCR and quantitative PCR provide rapid, highly sensitive detection for targeted assays. Each technology influences downstream requirements for bioinformatics, data management, and clinical validation, making technology selection a strategic decision rather than a purely technical one.

Applications drive prioritization across testing modalities. Hereditary disease diagnostics, which includes carrier screening and rare disease testing, requires high analytical sensitivity and interpretive expertise. Infectious disease testing, encompassing bacterial and viral detection, demands rapid turnaround and robust assay validation for clinical decision-making. Oncology testing, spanning liquid biopsy and solid tumor profiling, requires integrated workflows that connect tumor biology to therapeutic decision-support and monitoring. Pharmacogenomics and prenatal testing add layers of regulatory scrutiny and counseling needs that shape service delivery models.

End users span academic institutes, biotech and pharma companies, diagnostic laboratories, direct-to-consumer providers, and hospitals and clinics, each with unique operational imperatives. Academic research centers and universities prioritize exploratory capabilities and data access, while biotech and pharma companies focus on assay scalability and regulatory alignment for drug development. Diagnostic laboratories, whether hospital-based or independent, require validated, high-throughput processes and reliable supply channels. Direct-to-consumer channels, including online providers and retail clinic models, emphasize user experience, privacy, and simplified reporting. Hospitals and clinics, from large tertiary centers to specialized clinics, integrate testing into care pathways and must balance clinical utility with workflow efficiency.

Finally, service type segmentation-consumer, diagnostic, and research-clarifies routes to market and expectations for productization. Consumer offerings, which include ancestry and lifestyle and wellness tests such as fitness and nutrition-oriented reports, prioritize clarity of results and privacy safeguards. Diagnostic services, including clinical diagnostics and companion diagnostics, require rigorous compliance, clinical validation, and result interpretability. Research services, spanning preclinical and clinical research, demand flexibility, data depth, and integrative analytics. Viewing these segments together shows where investments in instrumentation, chemistry, informatics, and service design will yield the greatest clinical and commercial returns, and where partnerships and regulatory strategies will be most consequential.

Regional dynamics and cross-border considerations across the Americas, Europe Middle East and Africa, and Asia-Pacific shaping access, regulation, and innovation

Regional dynamics shape access, regulation, and commercialization strategies in distinct ways across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, the interplay between private laboratory networks, payer structures, and a mature regulatory framework accelerates clinical adoption for established diagnostic tests while creating pressure for differentiated, reimbursable value propositions. North and South markets vary in procurement practices and pricing sensitivity, which informs localized commercialization and distribution strategies.

The Europe Middle East and Africa region presents a complex mosaic where regulatory harmonization efforts in some jurisdictions coexist with fragmented payer and procurement landscapes in others. Data protection and cross-border sample movement rules are particularly influential, and vendors must navigate differing standards for clinical validation and laboratory accreditation. Meanwhile, Asia-Pacific spans advanced innovation hubs with strong domestic manufacturing and rapidly expanding clinical markets to regions where infrastructure and trained personnel remain bottlenecks; this diversity requires tiered go-to-market approaches that balance scalability with local partnership and capacity-building initiatives.

Across all regions, localization of manufacturing, digital health integration, and regulatory engagement have emerged as primary levers to expedite adoption and ensure continuity of supply. Strategic regional planning therefore must incorporate not only market opportunity but also infrastructure readiness, regulatory timelines, and partnerships that can bridge capability gaps while accelerating clinically meaningful deployments.

Strategic profiles and competitive positioning of leading genome testing companies, highlighting core differentiators in technology and service models

Leading companies in genome testing demonstrate different strategic emphases, from instrument innovation and integrated consumable ecosystems to software-led analytics and end-to-end sequencing services. Some organizations concentrate R&D on next generation sequencing chemistry and instrument engineering to deliver higher throughput and lower hands-on time. Others build competitive advantage through modular kit portfolios and reagent supply chains that lock in recurring revenue and simplify laboratory validation. A third group focuses on software platforms and analysis services that turn genomic outputs into clinically actionable reports, emphasizing interoperability, data security, and regulatory alignment.

Competitive positioning increasingly hinges on a company's ability to orchestrate partnerships across clinical laboratories, technology providers, and payers. Strategic alliances accelerate clinical validation and broaden access to patient cohorts, while vertical integration can reduce exposure to supply shocks but requires significant capital and regulatory oversight. Observing these patterns, it becomes clear that successful players balance product excellence with service quality and supply chain agility to sustain adoption and clinical credibility.

Practical operational recommendations for industry leaders to accelerate adoption, secure supply continuity, optimize clinical workflows, and expand access

Industry leaders should pursue a set of practical, operational actions that drive adoption, maintain continuity, and expand clinical impact. First, prioritize supply chain resilience by qualifying multiple suppliers for critical instruments, reagents, and consumables and by building regional sourcing or manufacturing relationships where feasible. This reduces exposure to tariff shifts and logistical disruption while shortening qualification cycles for clinical labs.

Second, invest in modular service offerings that pair validated kits with managed analysis and reporting services. Bundled solutions lower the barrier to clinical adoption by reducing the internal development burden on laboratories and clinical partners. Third, strengthen regulatory and reimbursement engagement early in product development. Proactive alignment with regulators and payers will shorten time-to-clinical integration and mitigate late-stage compliance risks.

Fourth, accelerate interoperability and data governance capabilities by adopting standard data models and robust privacy frameworks. This enables scalable analytics and facilitates collaborations across research institutions, healthcare systems, and commercial partners. Finally, design flexible commercial models that balance instrument sales with recurring revenues from kits, reagents, and analysis subscriptions. A diversified revenue approach both stabilizes cash flows and aligns vendor incentives with long-term clinical utility and customer success.

Transparent research methodology explaining data collection, expert interviews, validation processes, and analytical frameworks informing genome testing insights

The research methodology combines primary and secondary approaches to deliver validated, actionable insights. Primary data collection included structured interviews with domain experts across laboratory operations, clinical practice, and commercial leadership to understand real-world constraints and adoption drivers. These interviews were complemented by targeted engagements with procurement and quality assurance specialists to surface supply chain sensitivities and validation timelines.

Secondary research synthesized public literature, regulatory guidance documents, and technical white papers to map technology capabilities and standard-of-care applications. Data validation occurred through triangulation between expert testimony and documented regulatory pathways, and analytical frameworks were applied to identify cross-cutting themes such as technology adoption barriers, regulatory friction points, and service monetization vectors. Wherever possible, findings were stress-tested through scenario analysis to ensure relevance across different operational contexts.

Concise conclusion synthesizing key takeaways on technological advances, policy shifts, segmentation patterns, and regional factors shaping genome testing

The conclusion synthesizes core strategic implications from technological evolution, policy developments, segmentation complexity, and regional variability. Technology innovation continues to expand analytical possibilities while increasing integration needs for informatics and validated workflows. Policy and regulatory shifts demand early and sustained engagement to ensure clinical fit and patient safety, and segmentation analysis reveals that differentiated strategies are required for diagnostic, consumer, and research markets. Regional dynamics further complicate scale-up, making localized partnerships and supply chain strategies essential for durable market presence.

Taken together, these elements underscore that success in genome testing will depend on a balanced approach that combines technical excellence, regulatory foresight, operational resilience, and flexible commercial design. Organizations that align these capabilities will be better positioned to convert scientific promise into reliable clinical and commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genome Testing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Microarray Scanners
    • 8.1.2. PCR Machines
    • 8.1.3. Sequencers
  • 8.2. Kits
    • 8.2.1. Exome Kits
    • 8.2.2. Targeted Gene Kits
    • 8.2.3. Whole Genome Kits
  • 8.3. Reagents & Consumables
  • 8.4. Software & Services
    • 8.4.1. Analysis Services
    • 8.4.2. Data Storage Software
    • 8.4.3. Sequencing Services

9. Genome Testing Market, by Technology

  • 9.1. Microarray
    • 9.1.1. Expression Arrays
    • 9.1.2. SNP Arrays
  • 9.2. Next Generation Sequencing
    • 9.2.1. Illumina
    • 9.2.2. Ion Torrent
  • 9.3. PCR
    • 9.3.1. Digital PCR
    • 9.3.2. qPCR
  • 9.4. Sanger Sequencing

10. Genome Testing Market, by Service Type

  • 10.1. Consumer
    • 10.1.1. Ancestry
    • 10.1.2. Lifestyle & Wellness
      • 10.1.2.1. Fitness
      • 10.1.2.2. Nutrition
  • 10.2. Diagnostic
    • 10.2.1. Clinical Diagnostics
    • 10.2.2. Companion Diagnostics
  • 10.3. Research
    • 10.3.1. Clinical Research
    • 10.3.2. Preclinical Research

11. Genome Testing Market, by Application

  • 11.1. Hereditary Disease Testing
    • 11.1.1. Carrier Screening
    • 11.1.2. Rare Disease
  • 11.2. Infectious Disease Testing
    • 11.2.1. Bacterial Detection
    • 11.2.2. Viral Detection
  • 11.3. Oncology Testing
    • 11.3.1. Liquid Biopsy
    • 11.3.2. Solid Tumor Profiling
  • 11.4. Pharmacogenomics
  • 11.5. Prenatal Testing

12. Genome Testing Market, by End User

  • 12.1. Academic Institutes
    • 12.1.1. Research Centers
    • 12.1.2. Universities
  • 12.2. Biotech & Pharma Companies
    • 12.2.1. Biotech Companies
    • 12.2.2. Pharma Companies
  • 12.3. Diagnostic Laboratories
    • 12.3.1. Hospital Labs
    • 12.3.2. Independent Labs
  • 12.4. Direct To Consumer
    • 12.4.1. Online Providers
    • 12.4.2. Retail Clinics
  • 12.5. Hospitals & Clinics
    • 12.5.1. Large Hospitals
    • 12.5.2. Specialized Clinics

13. Genome Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Genome Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Genome Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Genome Testing Market

17. China Genome Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 10x Genomics
  • 18.6. 23andMe, Inc
  • 18.7. Abbott Laboratories
  • 18.8. Agilent Technologies, Inc.
  • 18.9. BGI Group
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. Danaher Corporation
  • 18.12. Eurofins Scientific SE
  • 18.13. F. Hoffmann-La Roche, Ltd.
  • 18.14. Freenome Holdings, Inc.
  • 18.15. GeneDx, LLC
  • 18.16. Genomic Testing Cooperative
  • 18.17. Helix OpCo, LLC
  • 18.18. Illumina, Inc.
  • 18.19. Merck KGaA
  • 18.20. New England Biolabs, Inc.
  • 18.21. Novogene Co, Ltd.
  • 18.22. Oxford Nanopore Technologies PLC
  • 18.23. PerkinElmer Inc.
  • 18.24. QIAGEN N.V.
  • 18.25. Quest Diagnostics Incorporated
  • 18.26. Takara Bio Inc
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. Ultima Genomics, Inc.
  • 18.29. VWR International, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOME TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOME TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENOME TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENOME TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOME TESTING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOME TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENOME TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOME TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENOME TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GENOME TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GENOME TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENOME TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENOME TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENOME TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENOME TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOME TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENOME TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENOME TESTING MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOME TESTING MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENOME TESTING MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOME TESTING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENOME TESTING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOME TESTING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENOME TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOME TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENOME TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOME TESTING MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOME TESTING MARKET SIZE, BY EXOME KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOME TESTING MARKET SIZE, BY EXOME KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENOME TESTING MARKET SIZE, BY EXOME KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOME TESTING MARKET SIZE, BY TARGETED GENE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENOME TESTING MARKET SIZE, BY TARGETED GENE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOME TESTING MARKET SIZE, BY TARGETED GENE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENOME TESTING MARKET SIZE, BY WHOLE GENOME KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOME TESTING MARKET SIZE, BY WHOLE GENOME KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENOME TESTING MARKET SIZE, BY WHOLE GENOME KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOME TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOME TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOME TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOME TESTING MARKET SIZE, BY ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOME TESTING MARKET SIZE, BY ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENOME TESTING MARKET SIZE, BY ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOME TESTING MARKET SIZE, BY DATA STORAGE SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENOME TESTING MARKET SIZE, BY DATA STORAGE SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOME TESTING MARKET SIZE, BY DATA STORAGE SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENOME TESTING MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOME TESTING MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENOME TESTING MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENOME TESTING MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOME TESTING MARKET SIZE, BY EXPRESSION ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOME TESTING MARKET SIZE, BY EXPRESSION ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOME TESTING MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENOME TESTING MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOME TESTING MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENOME TESTING MARKET SIZE, BY ILLUMINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOME TESTING MARKET SIZE, BY ILLUMINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENOME TESTING MARKET SIZE, BY ILLUMINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOME TESTING MARKET SIZE, BY ION TORRENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENOME TESTING MARKET SIZE, BY ION TORRENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOME TESTING MARKET SIZE, BY ION TORRENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENOME TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOME TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENOME TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOME TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENOME TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOME TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENOME TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOME TESTING MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENOME TESTING MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOME TESTING MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENOME TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOME TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENOME TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOME TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENOME TESTING MARKET SIZE, BY CONSUMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOME TESTING MARKET SIZE, BY CONSUMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENOME TESTING MARKET SIZE, BY CONSUMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOME TESTING MARKET SIZE, BY CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENOME TESTING MARKET SIZE, BY ANCESTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOME TESTING MARKET SIZE, BY ANCESTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENOME TESTING MARKET SIZE, BY ANCESTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOME TESTING MARKET SIZE, BY FITNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENOME TESTING MARKET SIZE, BY FITNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOME TESTING MARKET SIZE, BY FITNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENOME TESTING MARKET SIZE, BY NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOME TESTING MARKET SIZE, BY NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENOME TESTING MARKET SIZE, BY NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOME TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENOME TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOME TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENOME TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOME TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENOME TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOME TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENOME TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOME TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENOME TESTING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOME TESTING MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENOME TESTING MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOME TESTING MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENOME TESTING MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOME TESTING MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENOME TESTING MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENOME TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENOME TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENOME TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENOME TESTING MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GENOME TESTING MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENOME TESTING MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENOME TESTING MARKET SIZE, BY BACTERIAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENOME TESTING MARKET SIZE, BY BACTERIAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GENOME TESTING MARKET SIZE, BY BACTERIAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENOME TESTING MARKET SIZE, BY VIRAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GENOME TESTING MARKET SIZE, BY VIRAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENOME TESTING MARKET SIZE, BY VIRAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GENOME TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENOME TESTING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GENOME TESTING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENOME TESTING MARKET SIZE, BY SOLID TUMOR PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GENOME TESTING MARKET SIZE, BY SOLID TUMOR PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENOME TESTING MARKET SIZE, BY SOLID TUMOR PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GENOME TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENOME TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GENOME TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENOME TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GENOME TESTING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENOME TESTING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GENOME TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENOME TESTING MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL GENOME TESTING MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENOME TESTING MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL GENOME TESTING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENOME TESTING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL GENOME TESTING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENOME TESTING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL GENOME TESTING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENOME TESTING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL GENOME TESTING MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENOME TESTING MARKET SIZE, BY PHARMA COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL GENOME TESTING MARKET SIZE, BY PHARMA COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GENOME TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENOME TESTING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL GENOME TESTING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENOME TESTING MARKET SIZE, BY ONLINE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL GENOME TESTING MARKET SIZE, BY ONLINE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENOME TESTING MARKET SIZE, BY ONLINE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL GENOME TESTING MARKET SIZE, BY RETAIL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENOME TESTING MARKET SIZE, BY RETAIL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL GENOME TESTING MARKET SIZE, BY RETAIL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENOME TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL GENOME TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENOME TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GENOME TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENOME TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL GENOME TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENOME TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS GENOME TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS GENOME TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS GENOME TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS GENOME TESTING MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS GENOME TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS GENOME TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS GENOME TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS GENOME TESTING MARKET SIZE, BY CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS GENOME TESTING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS GENOME TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA GENOME TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA GENOME TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA GENOME TESTING MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA GENOME TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA GENOME TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA GENOME TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA GENOME TESTING MARKET SIZE, BY CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA GENOME TESTING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA GENOME TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA GENOME TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA GENOME TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA GENOME TESTING MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA GENOME TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA GENOME TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA GENOME TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA GENOME TESTING MARKET SIZE, BY CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA GENOME TESTING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA GENOME TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPE GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPE GENOME TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPE GENOME TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPE GENOME TESTING MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPE GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE GENOME TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPE GENOME TESTING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPE GENOME TESTING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPE GENOME TESTING MARKET SIZE, BY CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPE GENOME TESTING MARKET SIZE, BY LIFESTYLE & WELLNESS, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPE GENOME TESTING MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPE GENOME TESTING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPE GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPE GENOME TESTING MARKET SIZE, BY HEREDITARY DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPE GENOME TESTING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPE GENOME TESTING MARKET SIZE, BY ONCOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPE GENOME TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPE GENOME TESTING MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPE GENOME TESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPE GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 324. EUROPE GENOME TESTING MARKET SIZE, BY DIRECT TO CONSUMER, 2018-2032 (USD MILLION)
  • TABLE 325. EUROPE GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 326. MIDDLE EAST GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST GENOME TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. MIDDLE EAST GENOME TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST GENOME TESTING MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 330. MIDDLE EAST GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 332. MIDDLE EAST GENOME TESTING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 333. MIDDLE EAST GENOME TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLIO